This is a double-blind, randomised, multi-centre, placebo-controlled, comparative, phase IIb
trial. The trial will be conducted with three treatment groups in the form of a parallel
group comparison and will serve to compare oral treatment with either 1500 mg/d or 1000 mg/d
norUDCA tablets vs. placebo tablets for the treatment of NASH.